ClinicalTrials.gg
Drug

Ontamalimab clinical trials

Also written PF-00547659 and SHP647.

studies test it
12
open now
0
in phase 3
7
first study started
2011

How each study uses ontamalimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Ontamalimab
7
PF-00547659 SC Injection
2

Development codes

PF-00547659
8
SHP647
8
TAK-647
1

Studies by the year they started

12 studies that test it; most in 2018 (5)

Studies that test ontamalimab, by start year
YearStudies
20112
20121
20131
20171
20185
20191
20231

By phase

A phase 1/2 study counts in both.

Phase 1
1
Phase 2
4
Phase 3
7

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 12 · Other 0

Shire (11) · Takeda (1)

Studies

Open first, then newest update. How each study uses ontamalimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 12

Codes

What other systems call ontamalimab · ClinicalTrials.gg INT000217

  • MeSH (NLM) C000597368ontamalimabOne source NLM
  • UNII (FDA) 6LGI7RV4PBONTAMALIMABConfirmed FDA, NLM
  • NCI Thesaurus C166947OntamalimabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.